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Tauopathies including tau-associated Frontotemporal dementia (FTD) and Alzheimer’s dis-
ease are characterized pathologically by the formation of tau-containing neuroﬁbrillary
aggregates and neuronal loss, which contribute to cognitive decline.There are currently no
effective treatments to prevent or slow this neural systems failure. The rTg4510 mouse
model, which expresses a mutant form of the tau protein associated with FTD with
Parkinsonism-17, undergoes dramatic hippocampal and cortical neuronal loss making it
an ideal model to study treatments for FTD-related neuronal loss. Sirtuins are a family
of proteins involved in cell survival that have the potential to modulate neuronal loss in
neurodegenerative disorders. Here we tested the hypothesis that sirtuin 2 (SIRT2) inhibi-
tion would be non-toxic and prevent neurodegeneration in rTg4510 brain. In this study we
delivered SIRT2 inhibitor AK1 directly to the hippocampus with an osmotic minipump and
conﬁrmed that it reached the target region both with histological assessment of delivery
of a dye and with a pharmacodynamic marker, ABCA1 transcription, which was upregu-
lated with AK1 treatment. AK1 treatment was found to be safe in wild-type mice and in
the rTg4510 mouse model, and further, it provided some neuroprotection in the rTg4510
hippocampal circuitry. This study provides proof-of-concept for therapeutic beneﬁts of
SIRT2 inhibitors in both tau-associated FTD and Alzheimer’s disease, and suggests that
development of potent, brain permeable SIRT2 inhibitors is warranted.
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INTRODUCTION
Tauopathies are devastating conditions involving dramatic neu-
ronal loss and resulting circuit dysfunction for which there are
currently no effective treatments (Roberson, 2011). Investigation
of the neuroprotective effects of sirtuin modulation may pave
the way for future therapeutic studies in tauopathies and other
neurodegenerative disorders which share similar mechanisms of
degeneration (Spires and Hannan, 2007). Sirtuins are a fam-
ily of unique NAD+-dependent enzymes, which regulate diverse
cellular pathways, but are primarily involved in metabolic regu-
lation (Guarente and Picard, 2005; Michan and Sinclair, 2007).
Microtubule deacetylase sirtuin 2 (SIRT2) is a highly abundant
protein in CNS, which accumulates in the aging brain (Maxwell
et al., 2011). This is particularly interesting in tauopathies since
tau is a microtubule binding protein and microtubule-dependent
processes such as axonal transport are disrupted (Zhang et al.,
2005).
In vitro evidence indicates that sirtuin modulation may be
protective against amyloid toxicity in Alzheimer’s disease, par-
ticularly that activating SIRT1 can be protective (Chen et al.,
2005; Qin et al., 2006). Small molecule inhibitors of SIRT2
have also been found to ameliorate neurodegeneration in model
systems (Outeiro et al., 2008). For example, structurally diverse
selective SIRT2 inhibitors AGK2 (IC50 = 3.5μM) and AK1
(IC50 = 12.5μM) prevent alpha-synuclein toxicity in cell-based,
and Drosophila models of Parkinson’s (Outeiro et al., 2007). In
Huntington’s disease, both inhibitors, AGK2 and AK1, were pro-
tective against mutant polyglutamine toxicity in Drosophila and
C. elegans animal models and in primary striatal neurons (Luthi-
Carter et al., 2010). In the latter model, the protective effects of
SIRT2 inhibition were associated with reduced total cholesterol
levels due to facilitated cytoplasmic retention of sterol regulatory
element binding protein-2 (SREBP-2), a key transcriptional reg-
ulator of cholesterol biosynthesis genes in nuclei (Zhang et al.,
2005; Luthi-Carter et al., 2010; Taylor et al., 2011). However, SIRT2
inhibition caused broad changes in transcriptional expression of
metabolic genes. Cholesterol processing has also been implicated
in both Alzheimer’s disease (largely linked to amyloid processing)
and in other tauopathies. Loss of function of the NPC1 or NPC2
genes,which are involved in trafﬁcking cholesterol from lysosomes,
has been linked to Niemann–Pick disease type C disease which
includes tau pathology (Klunemann et al., 2002; Yu et al., 2005).
Further, in the THY-Tau22 mouse model of tauopathy, long-term
voluntary exercise prevented memory impairment and reduced
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hippocampal tau pathology associated with the upregulation of
the NPC1 and NPC2 genes (Belarbi et al., 2011).
The promising results in efﬁcacy of SIRT2 inhibition in two
neurodegenerative diseases, the mechanistic link between the
SIRT2 induced-downregulation of cholesterol biosynthesis, and
the association of cholesterol dysregulation in tauopathy led to
the hypothesis that SIRT2 inhibition may be neuroprotective in
tauopathy. Here we assess the safety of brain delivery of the
SIRT2 inhibitor AK1 in wild-type mice and in the rTg4510 trans-
genic model of tauopathy. The rTg4510 transgenic mouse model
expresses a human tau gene with a mutation associated with
familial frontotemporal dementia (FTD). These mice exhibit age-
related cognitive decline paralleled by the loss of neurons and
the formation of tau-containing neuroﬁbrillary tangles similar to
those seen in Alzheimer’s disease and FTD (SantaCruz et al., 2005;
Spires et al., 2006; Spires-Jones et al., 2008).
In this study,we sought to test effects of SIRT2 inhibition in vivo
and evaluate the safety of such an approach. Since neither of the
published high efﬁciency SIRT2 inhibitors AGK2 nor AK1 are
brain permeable, we selected a direct route for drug administra-
tion to mouse brain. Despite higher potency of SIRT2 inhibition,
AGK2 has poor water solubility (cLogP= 5.9) in contrast to AK1
(cLogP= 4.0), making AK1 the better choice for direct adminis-
tration to the brain. The high water solubility of sulfobenzoic acid
derivative AK1 also permits robust reduction of cholesterol by this
compound in striatal neurons (Luthi-Carter et al., 2010; Taylor
et al., 2011).
We ﬁnd that infusion of AK1 with an osmotic minipump
directly into the hippocampus of mice for 5weeks does not cause
any neuronal loss in the CornuAmmonis 1 (CA1) or dentate gyrus
(DG) regions of the hippocampus compared to the untreated
hemispheres or vehicle control treatment, even in the context of a
tau transgenic mouse which is susceptible to neuronal loss. Fur-
thermore, we observe a modest prevention of neuronal loss in the
DG of rTg4510 mice, indicating that inhibition of SIRT2 is a safe
and promising neuroprotective agent.
MATERIALS AND METHODS
ANIMALS AND SURGERY
Animals used in this study were mixed gender rTg4510 mice
expressing both human mutant P301L tau downstream of a
tetracycline-operon-responsive element tau-P301L and an acti-
vator tetracycline-off transgene controlled by Ca2+-calmodulin
kinase II promoter elements and littermate “wild-type” controls
(which do not have a phenotype) expressing only the activator
transgene (without tau; SantaCruz et al., 2005). Table 1 shows the
numbers of animals used at each age. Each animal had an osmotic
minipump (Alzet 2006, DURECT Corporation, Cupertino, CA,
USA) implanted,which pumped drug or vehicle for 5weeks before
sacriﬁce. A further six wild-type animals were used for 1week
studies: three had a pump with 0.05% trypan blue in 5% DMSO
implanted for 1week to verify cannula implantation coordinates
and the spread of pumped solution through the hippocampus
(Figure 1E) and three more received AK1 treatment for 1week
followed by gene expression analysis using qPCR. Before implan-
tation, pumps with cannulas were assembled, ﬁlled with 50μM
AK1 [3-(1-azepanylsulfonyl)-N-(3-nitrophenyl)benzamide from
Table 1 | Animals used in the study.
Genotype Age at sacrifice (month) Treatment n
Wild-type 5.5 AK1 3
Wild-type 5.5 vehicle 3
Wild-type 7 AK1 5
Wild-type 7 vehicle 5
rTg4510 5.5 AK1 4
rTg4510 5.5 vehicle 5
rTg4510 7 AK1 7
rTg4510 7 Vehicle 5
ChemBridge, diluted 1:200 in PBS from 10mM stock in DMSO],
or vehicle (1:200 DMSO:PBS) and incubated at 37˚C for 60 h to
prime the pumps. To asses safety, we used the maximum concen-
tration of AK1 (50μM) that kept the DMSO levels to a maximum
of 5%, above which DMSO can become neurotoxic (Cavas et al.,
2005).Animals were anesthetizedwith ketamine/xylazine anesthe-
sia (100mg/kg ketamine, 10mg/kg xylazine, i.p.), the pump body
inserted subcutaneously over the mid-scapular area, and the can-
nulawas implanted into the right hippocampal formation through
a burr hole at coordinates−2.0 posterior to Bregma and 1.5mm to
the right of themidline, 1.8mmdeep (Figure 1C). Five weeks after
pump implantation, animals were sacriﬁced with carbon dioxide,
and brains removed and ﬁxed in 4% paraformaldehyde for 48 h
followed by parafﬁn embedding. Each cannulawas tested to ensure
it was not blocked and the pumps examined to ensure the com-
pound was not remaining in the pump. Due to pump failures,
group sizes are not equal. Table 1 reﬂects numbers of animals in
each group that were analyzed (pumps worked). All animal work
conforms to institutional and NIH guidelines.
IMMUNOHISTOCHEMISTRY AND STEREOLOGY
Parafﬁn embedded brain hemispheres were cut in sagittal ori-
entation in 16μm sections. Every 30th section throughout the
hippocampal formation was deparafﬁnized and stained with anti
PHF-1 tau primary antibody (1:200 in 1% milk, courtesy Dr
Peter Davies), and anti mouse IgG secondary antibody conju-
gated to Cy3 (1:500, Jackson ImmunoResearch) and nuclei coun-
terstained with DAPI (4′,6-diamidino-2-phenylindole). Sections
were observed on an upright Olympus BX51 ﬂuorescence micro-
scope with a DP70 camera and a stereology image analysis system
(CAST; Olympus, Denmark). Neuronal nuclei were identiﬁed
based on morphology as described previously (Spires et al., 2006;
Fox et al., 2011).
Neuron densities and PHF1 positive neuron densities in the
CA1 pyramidal cell layer and DG granular layer were estimated
using the optical fractionator method, volumes of these regions
estimated using the Cavalieri method, and total neuron number
in CA1 and DG calculated as previously described (Spires et al.,
2006).
CELL CULTURE
Primary cortical neurons were prepared from mouse embryos at
embryonic day 15 and cultured inneurobasalmedia supplemented
with 2% B-27 and 1% penicillin/streptomycin. At 7 days in vitro,
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FIGURE 1 | AK1 affects ABCA1 transcription in vitro and in vivo.
Treatment of cultured primary cortical neurons with SIRT2 inhibitors AK1,
AK7, and AGK2 caused an increase in ABCA1 mRNA levels (A). AK1
[structure shown in (B)] was pumped into the hippocampus of mice [site
shown in (C)]. As seen in cultured neurons, 1week of treatment in
wild-type mice increases ABCA1 expression in the treated hemisphere
compared to the untreated hemisphere [(D), p<0.05], indicating the drug
reached the brain. Trypan blue pumped for 7 days further conﬁrms the
cannula placement in the hippocampus and shows spread of pumped
material through the entire hippocampal formation (E).
neurons were treated for 24 h with 1μM or 10μM AK7, AGK2,
or AK1 (from ChemBridge, San Diego, CA, USA). Neurons were
then harvested and homogenized for RNA extraction as described
below.
QUANTITATIVE PCR
Three wild-type mice were treated with AK1 administration to
the right hippocampus for 1week. At the end of the week, mice
were sacriﬁced, brains removed and the hemispheres frozen sep-
arately. Tissue was homogenized in RNase free lysis buffer con-
taining 50mM tris buffer, 175mM NaCl, 5mM EDTA, RNase
inhibitors (Ambion AM2694), and proteinase inhibitor cocktail
(Roche Complete Mini). RNA was isolated with the Stratagene
Absolutely RNA Miniprep kit and cDNA generated using Super-
Script reverse Transcriptase (Invitrogen). Quantitative PCR was
run on an iCycler (Bio-Rad, Hercules, CA, USA) using GAPDH
as a standard housekeeping gene and ABCA1 with the following
primers: left, gctcaatgtcatccgtcttc; right, ctggaaacacactttccttatc.
STATISTICS
Statistical tests were run using JMP software (SAS Institute, Cary,
NC, USA). Normality of data was assessed using a Shapiro–Wilk
test. Non-normal data (including stereological measures) were
analyzed with non-parametric tests (Kruskal–Wallis for multiple
comparisons, post hoc Wilcoxon tests to compare groups). Normal
data (ABCA1 expression) were analyzed with parametric statistics
(t -tests for two groups, ANOVA for multiple groups). p< 0.05
is considered signiﬁcant. Data are presented as mean± standard
deviation from the mean.
RESULTS
AK1 ADMINISTRATION TO THE BRAIN IS NOT NEUROTOXIC
Previous work has shown that SIRT2 inhibition with compounds
AGK2, AK1, and AK7 affects transcription of genes involved in
cholesterol pathways in striatal neuronal cultures (Luthi-Carter
et al., 2010; Taylor et al., 2011). We veriﬁed this in primary corti-
cal neuronal cultures (Figure 1A), where we observed an increase
in mRNA levels of ATP-binding cassette transporter ABCA1 (a
known transporter of cholesterol) with SIRT2 inhibition. AK1
showed the highest efﬁciency in this test in our cortical cul-
tures, and it is known to be protective in vitro against toxicity
of mutant huntingtin and alpha-synuclein (Outeiro et al., 2007;
Luthi-Carter et al., 2010), thus we moved forward to test the
safety and efﬁcacy of AK1 in treating tauopathy model mice. To
test the safety of administering the SIRT2 inhibitor AK1 (struc-
ture shown in Figure 1B) directly to the brain, we ﬁlled osmotic
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minipumps with a solution of 50μM AK1 in PBS (with 0.5%
DMSO) or vehicle and pumped the solution into the hippocam-
pus for 5weeks (Figure 1C). In three wild-type mice treated with
AK1 for 1week then sacriﬁced for molecular analysis of the brain,
we conﬁrmed that AK1 increased expression of ABCA1 in the
treated versus untreated hemisphere (146.9% higher in treated
versus untreated hemisphere, Figure 1D). This indicates that AK1
may act through modulating cholesterol homeostasis as previ-
ously reported (Zhang et al., 2005; Luthi-Carter et al., 2010; Taylor
et al., 2011). Further, this is a pharmacodynamic marker reporting
compound activity in the brain, indicating the AK1 successfully
reached the brain tissue. Tests pumping 0.05% trypan blue for
1week conﬁrmed the delivery of the blue dye throughout the
hippocampus (Figure 1E), further conﬁrming the delivery of com-
pound through the entire region of interest that we want to treat
in models of tau-induced neurodegeneration.
After these preliminary studies pumping the drug into the brain
for 1week conﬁrmed delivery of the drug to the brain and showed
a pharmacodynamic response, we treated mice for 5weeks, which
is a therapeutic window long enough to observe neuronal death
in mouse models of neurodegeneration. After pumping AK1 or
vehicle for 5weeks (from approximately 4 to 5.5months of age),
neuron numbers in the CA1 and DG regions of the hippocampus
were estimatedusing stereology. Inwild-typemice,we observedno
neuronal loss after pumping AK1 compared to the vehicle control
(Figure 2A). Comparing the treated versus untreated hemispheres
in individual animals also revealed no loss in the treated side, indi-
cating the placement of the cannula itself does not cause detectable
neuronal loss (Figure 2C).
rTg4510 mice undergo neuronal loss in the hippocampus, thus
we tested whether implantation of the cannula or the AK1 com-
pound itself cause any neuronal loss in this model which is suscep-
tible to neurodegeneration. As seen in the wild-type littermates,
5 weeks of vehicle or AK1 treatment from 4 to 5.5months of age
did not cause any neuronal loss in the CA1 or DG of rTg4510mice
(Figures 2B,D).
AK1 DOES NOT AFFECT NEUROFIBRILLARY TANGLE FORMATION
In cellular models of Parkinson’s disease, SIRT2 inhibition with
AK1 prevented alpha-synucleinmediated cell death and also inter-
estingly promoted alpha-synuclein aggregate formation (Outeiro
et al., 2007). Thus we tested whether AK1 treatment from 4 to
5.5months of age changed the number of neuroﬁbrillary tangles
in the brains of treated rTg4510mice. In previous studies, we have
shown that PHF1 staining in rTg4510 mice corresponds exactly
to Bielchowski positive neuroﬁbrillary tangles at these ages (Spires
et al., 2006), thus PHF1 immunostaining was used to characterize
neuroﬁbrillary pathology. Stereological counts of PHF1 positive
neurons show no effect of AK1 treatment on tangle numbers
either when compared to vehicle treatment or when compared
to the contralateral hemisphere (Figure 3), indicating that SIRT2
inhibition in vivo does not affect neuroﬁbrillary tangle formation
or stability.
POTENTIAL NEUROPROTECTIVE EFFECTS OF AK1 TREATMENT
rTg4510 mice undergo neuronal loss in the hippocampus and
neocortex that is associated with behavioral deﬁcits (SantaCruz
et al., 2005; Spires et al., 2006), and neuronal loss correlates
with dementia in FTD and Alzheimer’s disease (DeKosky and
Scheff, 1990; DeKosky et al., 1996). In control animals, there
is no effect of age or treatment on the number of neurons
in the DG granular cell layer (1.57× 105 ± 0.85× 105 neu-
rons per hemisphere, p> 0.05 with treatment and age as inde-
pendent variables, split by genotype). We observe a 42% loss
of DG neurons between 5.5 and 7months in vehicle treated
rTg4510 mice from 1.6× 105 ± 0.3× 105 neurons/hemisphere to
FIGURE 2 | AK1 delivery to the hippocampus is non-toxic. AK1 administration from 4 to 5.5months of age does not cause neurodegeneration in wild-type
(A) or rTg4510 hippocampus (B). Placement of the cannula in the treated hemisphere does not cause unilateral neuron loss in wild-type (C) or rTg4510 (D)
hippocampus.
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0.9× 105 ± 0.1× 105 neurons/hemisphere (p = 0.009, Wilcoxon
test). This loss was partially prevented by AK1 treatment
(Figure 4). rTg4510 mice treated with AK1 had signiﬁcantly
higher numbers of DG neurons than vehicle treated rTg4510mice
at 7months (p = 0.03, Wilcoxon test), and they are not signiﬁ-
cantly different from control animals (control p> 0.05). These
results indicate that AK1 treatment may be neuroprotective in
tauopathy.
DISCUSSION
There is a pressing need to develop neuroprotective therapies for
tauopathies including tau-associated FTDandAlzheimer’s disease,
for which there are currently no effective treatments (Rober-
son, 2011). One promising therapeutic avenue is manipulation
of sirtuins. In particular, SIRT2 inhibition has been shown to
be neuroprotective in neuronal cell culture and invertebrate ani-
mal models of Parkinson’s and Huntington’s diseases (Outeiro
FIGURE 3 | AK1 treatment does not affect numbers of PHF1-positive
neurofibrillary tangles. Micrographs from rTg4510 mice treated from 4 to
5.5months with vehicle (A) or AK1 (B) show that both treatment groups have
PHF1 positive neuroﬁbrillary tangles (red) in the treated CA1. Quantiﬁcation
reveals no difference in the numbers of tangles in the treated and untreated
hemispheres either when all animals are averaged (C) or when a ratio of
treated/untreated hemisphere is calculated for each animal before
averaging (D).
FIGURE 4 | AK1 treatment partially protects against tau-induced
neurodegeneration. Micrographs of DAPI staining of the dentate gyrus (A)
demonstrate the loss of neurons in rTg4510 mice compared to control mice
at 7months of age. rTg4510 mice treated with vehicle from 5.5 to 7months
of age underwent neuronal loss, compared both to wild-type and
5.5-month-old rTg4510 animals (B, *p<0.05). AK1 treatment partially
prevented this loss. AK1 treated rTg4510 DG does not have signiﬁcant loss
compared to wild-type or 5.5-month-old rTg4510 brain.
www.frontiersin.org March 2012 | Volume 3 | Article 42 | 5
Spires-Jones et al. Sirtuin inhibition neuroprotective in FTD
et al., 2007; Luthi-Carter et al., 2010). Due to the ongoing dis-
cussion and controversy on the therapeutic role of sirtuins in
neurodegeneration, it was imperative to assess the properties of
SIRT2 inhibition on the brain directly. While we cannot rule
out off-target effects of the AK1 compound, it is the case that
most marketed drugs interact with multiple targets yet medi-
ate therapeutic effects. The purpose of this study was to assess
preliminary toxicity and efﬁcacy of a SIRT2 inhibitor belonging
to a therapeutically promising structural scaffold of sulfoben-
zoic acid derivatives, prior to medicinal chemical optimization
for drug-like properties, brain permeability, bioavailability, and
bioactivity.
Tauopathies are characterized by the accumulation of aggre-
gated tau pathology and neuronal loss. In this study, we tested
whether inhibition of SIRT2 with AK1 delivery directly to the
hippocampus could prevent neuronal loss in rTg4510 mice. We
ﬁnd that in both wild-type and rTg4510 brain, AK1 treatment
was non-toxic to neurons (no neurons were lost with treatment
from 4 to 5.5months). Furthermore, between 5.5 and 7months
of age, neurons are lost in the DG of rTg4510 mice, and this
is partially prevented by AK1 treatment. It is worth noting that
the neuronal counts in this study show a phenotypic drift toward
delayed neuronal loss in our rTg4510 colony with no neuronal
loss in CA1 or DG between 4 and 5.5months and no loss in
CA1 between 5.5 and 7months,whereas previous characterization
of this model by our group found a steep decline in hippocam-
pal neuron numbers in rTg4510 mice between 4 and 5.5months
of age (Spires et al., 2006). In Alzheimer’s disease, neuroﬁbril-
lary tangles were classically viewed as toxic since they correlate
with cognitive decline, but new evidence has emerged suggest-
ing that soluble forms of tau may be more toxic than aggregates
(Spires-Jones et al., 2009). As such, it is important when develop-
ing new pharmacological targets to assess their effects both on
neuronal loss and on tau aggregates. Here, we observe neuro-
protection in the hippocampus without affecting neuroﬁbrillary
tangle pathology, lending support to the hypothesis that soluble
tau is neurotoxic.
The mechanisms of tau toxicity are unclear but there is
some evidence implicating altered cholesterol processing in the
neurodegenerative process (Klunemann et al., 2002;Yu et al., 2005;
Belarbi et al., 2011), and SIRT2 inhibition is known to modulate
cholesterol biosynthesis in cultured neurons (Taylor et al., 2011).
Here we conﬁrm in vivo that the expression of ABCA1, which is a
major regulator of cholesterol homeostasis, is affected in the brain
with SIRT2 inhibition by AK1.
While the complexity of osmotic minipump studies resulted
in the methodological limitation of a small number of animals
that completed the study successfully in each group, we were still
able with these small numbers to observe a modest beneﬁcial
effect of AK1 treatment and conﬁrm that there is no overt neu-
ronal loss induced by this compound. This study provides three
important new pieces of information to the ﬁeld of treatment for
neurodegenerative tauopathies: (1) SIRT2 inhibition in the brain is
non-toxic in wild-type and FTDmodel mice, (2) SIRT2 inhibition
with AK1 does not affect neuroﬁbrillary pathology in this model,
and (3) AK1 treatment protects hippocampal neurons to some
extent from degeneration. Osmotic minipump administration of
drugs directly to the brain circumvents the blood–brain-barrier
and allowed us to test the safety and efﬁcacy of SIRT2 inhibition
in vivo. However, this technique is technically difﬁcult and not
ideal for human patients. Our results suggest that the development
of a potent, brain permeable compound to inhibit SIRT2 would
be a good therapeutic avenue for tauopathies including FTD and
Alzheimer’s disease.
This studywas funded by theAlzheimer’s Disease DrugDiscov-
ery Foundation and theAssociation for FrontotemporalDegenera-
tion,HarvardMedical School ClaﬂinAward,NIHgrantsAG08487,
K99AG33670, and theAlzheimer’sAssociationZenithAward. Ren-
ovations toMcLaughlinResearch Institute’sAnimalResourceCen-
ter were funded by major grants and donations from the M. J.
Murdock Charitable Trust, Montana’s Department of Commerce,
the Browning-Kimball Foundation, the Oakland family, Sletten
Construction, and Ian & Nancy Davidson. We thank Prof Brad
Hyman for his discussions on the project.
REFERENCES
Belarbi, K., Burnouf, S., Fernandez-
Gomez, F. J., Laurent, C., Lestavel,
S., Figeac, M., Sultan, A., Tro-
quier, L., Leboucher, A., Caillierez,
R., Grosjean, M. E., Demeyer, D.,
Obriot, H., Brion, I., Barbot, B.,
Galas, M. C., Staels, B., Humez, S.,
Sergeant, N., Schraen-Maschke, S.,
Muhr-Tailleux, A., Hamdane, M.,
Buee, L., and Blum, D. (2011). Ben-
eﬁcial effects of exercise in a trans-
genic mouse model of Alzheimer’s
disease-like Tau pathology. Neuro-
biol. Dis. 43, 486–494.
Cavas, M., Beltran, D., and Navarro,
J. F. (2005). Behavioural effects
of dimethyl sulfoxide (DMSO):
changes in sleep architec-
ture in rats. Toxicol. Lett. 157,
221–232.
Chen, J., Zhou, Y., Mueller-Steiner,
S., Chen, L. F., Kwon, H., Yi, S.,
Mucke, L., and Gan, L. (2005).
SIRT1 protects against microglia-
dependent amyloid-beta toxicity
through inhibiting NF-kappaB
signaling. J. Biol. Chem. 280,
40364–40374.
DeKosky, S. T., and Scheff, S. W. (1990).
Synapse loss in frontal cortex
biopsies in Alzheimer’s disease:
correlation with cognitive severity.
Ann. Neurol. 27, 457–464.
DeKosky, S. T., Scheff, S. W., and
Styren, S. D. (1996). Structural
correlates of cognition in dementia:
quantiﬁcation and assessment of
synapse change. Neurodegeneration
5, 417–421.
Fox, L. M.,William, C. M., Adamowicz,
D. H., Pitstick, R., Carlson, G. A.,
Spires-Jones, T. L., and Hyman, B.
T. (2011). Soluble tau species, not
neuroﬁbrillary aggregates, disrupt
neural system integration in a tau
transgenic model. J. Neuropathol.
Exp. Neurol. 70, 588–595.
Guarente, L., and Picard, F. (2005).
Calorie restriction – the SIR2
connection. Cell 120, 473–482.
Klunemann, H. H., Elleder, M.,
Kaminski, W. E., Snow, K., Peyser,
J. M., O’Brien, J. F., Munoz, D.,
Schmitz, G., Klein, H. E., and
Pendlebury, W. W. (2002). Frontal
lobe atrophy due to a mutation
in the cholesterol binding pro-
tein HE1/NPC2. Ann. Neurol. 52,
743–749.
Luthi-Carter, R., Taylor, D. M., Pal-
los, J., Lambert, E., Amore, A.,
Parker, A., Mofﬁtt, H., Smith, D.
L., Runne, H., Gokce, O., Kuhn,
A., Xiang, Z., Maxwell, M. M.,
Reeves, S. A., Bates, G. P., Neri,
C., Thompson, L. M., Marsh, J. L.,
and Kazantsev, A. G. (2010). SIRT2
inhibition achieves neuroprotection
by decreasing sterol biosynthesis.
Proc. Natl. Acad. Sci. U.S.A. 107,
7927–7932.
Maxwell, M. M., Tomkinson, E. M.,
Nobles, J., Wizeman, J. W., Amore,
A. M., Quinti, L., Chopra, V.,
Hersch, S. M., and Kazantsev, A. G.
(2011). The Sirtuin 2 microtubule
deacetylase is an abundant neuronal
protein that accumulates in the
aging CNS. Hum. Mol. Genet. 20,
3986–3996.
Michan, S., and Sinclair, D. (2007).
Sirtuins in mammals: insights into
their biological function. Biochem.
J. 404, 1–13.
Outeiro, T. F., Kontopoulos, E., Alt-
mann, S.M.,Kufareva, I., Strathearn,
K. E., Amore, A. M., Volk, C. B.,
Maxwell, M. M., Rochet, J. C.,
Mclean, P. J., Young, A. B., Abagyan,
R., Feany, M. B., Hyman, B. T., and
Kazantsev, A. G. (2007). Sirtuin 2
inhibitors rescue alpha-synuclein-
mediated toxicity in models of
Parkinson’s disease. Science 317,
516–519.
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery March 2012 | Volume 3 | Article 42 | 6
Spires-Jones et al. Sirtuin inhibition neuroprotective in FTD
Outeiro, T. F., Marques, O., and Kazant-
sev, A. (2008). Therapeutic role of
sirtuins in neurodegenerative dis-
ease. Biochim. Biophys. Acta 1782,
363–369.
Qin, W., Yang, T., Ho, L., Zhao, Z.,
Wang, J., Chen, L., Zhao, W., Thiya-
garajan,M.,Macgrogan,D.,Rodgers,
J. T., Puigserver, P., Sadoshima, J.,
Deng, H., Pedrini, S., Gandy, S.,
Sauve, A. A., and Pasinetti, G. M.
(2006). Neuronal SIRT1 activation
as a novel mechanism underlying
the prevention of Alzheimer disease
amyloid neuropathology by calo-
rie restriction. J. Biol. Chem. 281,
21745–21754.
Roberson, E. D. (2011). Contempo-
rary approaches to Alzheimer’s
disease and frontotemporal demen-
tia. Methods Mol. Biol. 670,
1–9.
SantaCruz, K., Lewis, J., Spires, T., Paul-
son, J., Kotilinek, L., Ingelsson, M.,
Guimaraes, A., Deture, M., Rams-
den, M., Mcgowan, E., Forster, C.,
Yue, M., Orne, J., Janus, C., Mari-
ash, A., Kuskowski, M., Hyman, B.,
Hutton, M., and Ashe, K. H. (2005).
Tau suppression in a neurode-
generative mouse model improves
memory function. Science 309,
476–481.
Spires, T. L., and Hannan, A. J. (2007).
Molecular mechanisms mediating
pathological plasticity in Hunting-
ton’s disease andAlzheimer’s disease.
J. Neurochem. 100, 874–882.
Spires, T. L., Orne, J. D., SantaCruz,
K., Pitstick, R., Carlson, G. A.,
Ashe, K. H., and Hyman, B. T.
(2006). Region-speciﬁc dissociation
of neuronal loss and neuroﬁbril-
lary pathology in a mouse model
of tauopathy. Am. J. Pathol. 168,
1598–1607.
Spires-Jones, T. L., De Calignon, A.,
Matsui, T., Zehr, C., Pitstick, R., Wu,
H. Y., Osetek, J. D., Jones, P. B., Bac-
skai, B. J., Feany, M. B., Carlson, G.
A.,Ashe,K.H., Lewis, J., andHyman,
B. T. (2008). In vivo imaging reveals
dissociation between caspase activa-
tion and acute neuronal death in
tangle-bearing neurons. J. Neurosci.
28, 862–867.
Spires-Jones, T. L., Stoothoff, W. H.,
De Calignon, A., Jones, P. B., and
Hyman, B. T. (2009). Tau patho-
physiology in neurodegeneration: a
tangled issue. Trends Neurosci. 32,
150–159.
Taylor, D. M., Balabadra, U., Xiang, Z.,
Woodman, B., Meade, S., Amore, A.,
Maxwell, M. M., Reeves, S., Bates, G.
P., Luthi-Carter, R., Lowden, P. A.,
andKazantsev,A.G. (2011).Abrain-
permeable small molecule reduces
neuronal cholesterol by inhibiting
activity of sirtuin 2 deacetylase. ACS
Chem. Biol. 6, 540–546.
Yu, W., Ko, M., Yanagisawa, K., and
Michikawa, M. (2005). Neu-
rodegeneration in heterozygous
Niemann–Pick type C1 (NPC1)
mouse: implication of heterozygous
NPC1 mutations being a risk for
tauopathy. J. Biol. Chem. 280,
27296–27302.
Zhang, B.,Maiti,A., Shively, S., Lakhani,
F.,Mcdonald-Jones,G.,Bruce, J.,Lee,
E. B., Xie, S. X., Joyce, S., Li, C.,
Toleikis, P. M., Lee, V. M., and Tro-
janowski, J. Q. (2005). Microtubule-
binding drugs offset tau seques-
tration by stabilizing microtubules
and reversing fast axonal trans-
port deﬁcits in a tauopathy model.
Proc. Natl. Acad. Sci. U.S.A. 102,
227–231.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 30 January 2012; paper pending
published: 18 February 2012; accepted:
24 February 2012; published online: 12
March 2012.
Citation: Spires-Jones TL, Fox LM,
Rozkalne A, Pitstick R, Carlson GA and
Kazantsev AG (2012) Inhibition of sir-
tuin 2 with sulfobenzoic acid derivative
AK1 is non-toxic and potentially neuro-
protective in a mouse model of frontotem-
poral dementia. Front. Pharmacol. 3:42.
doi: 10.3389/fphar.2012.00042
This article was submitted to Frontiers
in Experimental Pharmacology andDrug
Discovery, a specialty of Frontiers in
Pharmacology.
Copyright © 2012 Spires-Jones, Fox,
Rozkalne, Pitstick, Carlson and
Kazantsev. This is an open-access
article distributed under the terms of
the Creative Commons Attribution Non
Commercial License, which permits
non-commercial use, distribution, and
reproduction in other forums, provided
the original authors and source are
credited.
www.frontiersin.org March 2012 | Volume 3 | Article 42 | 7
